Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 185

1.

Biomarkers of Targeted Therapy and Immuno-Oncology in Cancers Metastatic to the Breast.

Vranic S, Senarathne W, Stafford P, Poorman K, Pockaj BA, Gatalica Z.

Appl Immunohistochem Mol Morphol. 2019 Sep 11. doi: 10.1097/PAI.0000000000000808. [Epub ahead of print]

PMID:
31517642
2.

Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden, and PD-L1 expression in cancer patients.

Nikanjam M, Arguello D, Gatalica Z, Swensen J, Barkauskas DA, Kurzrock R.

Int J Cancer. 2019 Sep 3. doi: 10.1002/ijc.32661. [Epub ahead of print]

PMID:
31479512
3.

Immunohistochemistry-Enabled Precision Medicine.

Gatalica Z, Feldman R, Vranić S, Spetzler D.

Cancer Treat Res. 2019;178:111-135. doi: 10.1007/978-3-030-16391-4_4.

PMID:
31209843
4.

Secretory Carcinoma of the Skin: Report of 6 Cases, Including a Case With a Novel NFIX-PKN1 Translocation.

Kastnerova L, Luzar B, Goto K, Grishakov V, Gatalica Z, Kamarachev J, Martinek P, Hájková V, Grossmann P, Imai H, Fukui H, Michal M, Kazakov DV.

Am J Surg Pathol. 2019 Aug;43(8):1092-1098. doi: 10.1097/PAS.0000000000001261.

PMID:
31045890
5.

Detection of NRG1 Gene Fusions in Solid Tumors.

Jonna S, Feldman RA, Swensen J, Gatalica Z, Korn WM, Borghaei H, Ma PC, Nieva JJ, Spira AI, Vanderwalde AM, Wozniak AJ, Kim ES, Liu SV.

Clin Cancer Res. 2019 Aug 15;25(16):4966-4972. doi: 10.1158/1078-0432.CCR-19-0160. Epub 2019 Apr 15.

PMID:
30988082
6.

S100 and CD34 positive spindle cell tumor with prominent perivascular hyalinization and a novel NCOA4-RET fusion.

Michal M, Ptáková N, Martínek P, Gatalica Z, Kazakov DV, Michalová K, Stoláriková L, Švajdler M, Michal M.

Genes Chromosomes Cancer. 2019 Sep;58(9):680-685. doi: 10.1002/gcc.22758. Epub 2019 Apr 16.

PMID:
30938880
7.

Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer.

Cyprian FS, Akhtar S, Gatalica Z, Vranic S.

Bosn J Basic Med Sci. 2019 Aug 20;19(3):227-233. doi: 10.17305/bjbms.2019.4204. Review.

8.

NUTM1-rearranged neoplasia: a multi-institution experience yields novel fusion partners and expands the histologic spectrum.

Stevens TM, Morlote D, Xiu J, Swensen J, Brandwein-Weber M, Miettinen MM, Gatalica Z, Bridge JA.

Mod Pathol. 2019 Jun;32(6):764-773. doi: 10.1038/s41379-019-0206-z. Epub 2019 Feb 5.

PMID:
30723300
9.

Theranostic molecular profiling of pleomorphic ductal carcinoma of the breast.

Vranic S, Palazzo J, Swensen J, Xiu J, Florento E, Gatalica Z.

Breast J. 2019 Jan;25(1):175-176. doi: 10.1111/tbj.13187. Epub 2018 Dec 18. No abstract available.

PMID:
30565349
10.

Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast.

Vranic S, Palazzo J, Sanati S, Florento E, Contreras E, Xiu J, Swensen J, Gatalica Z.

Clin Breast Cancer. 2019 Apr;19(2):131-136. doi: 10.1016/j.clbc.2018.09.001. Epub 2018 Sep 5.

11.

Molecular characterization of cancers with NTRK gene fusions.

Gatalica Z, Xiu J, Swensen J, Vranic S.

Mod Pathol. 2019 Jan;32(1):147-153. doi: 10.1038/s41379-018-0118-3. Epub 2018 Aug 31.

PMID:
30171197
12.

Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies.

Willenbacher W, Seeber A, Steiner N, Willenbacher E, Gatalica Z, Swensen J, Kimbrough J, Vranic S.

Int J Mol Sci. 2018 Jul 18;19(7). pii: E2087. doi: 10.3390/ijms19072087. Review.

13.

Profiles of brain metastases: Prioritization of therapeutic targets.

Ferguson SD, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos PK, Kesari S, Hu J, Rudnick J, Salacz ME, Piccioni D, Huang S, Davies MA, Glitza IC, Heymach JV, Zhang J, Ibrahim NK, DeGroot JF, McCarty J, O'Brien BJ, Sawaya R, Verhaak RGW, Reddy SK, Priebe W, Gatalica Z, Spetzler D, Heimberger AB.

Int J Cancer. 2018 Dec 1;143(11):3019-3026. doi: 10.1002/ijc.31624. Epub 2018 Oct 9.

14.

Rethinking medulloblastoma from a targeted therapeutics perspective.

Hashimoto Y, Penas-Prado M, Zhou S, Wei J, Khatua S, Hodges TR, Sanai N, Xiu J, Gatalica Z, Kim L, Kesari S, Rao G, Spetzler D, Heimberger A.

J Neurooncol. 2018 Sep;139(3):713-720. doi: 10.1007/s11060-018-2917-2. Epub 2018 Jun 5.

15.

Spindle Epithelial Tumor with Thymus-Like Differentiation (SETTLE): A Next-Generation Sequencing Study.

Stevens TM, Morlote D, Swensen J, Ellis M, Harada S, Spencer S, Prieto-Granada CN, Folpe AL, Gatalica Z.

Head Neck Pathol. 2019 Jun;13(2):162-168. doi: 10.1007/s12105-018-0927-1. Epub 2018 May 7.

16.

Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas.

Ferguson SD, Zhou S, Huse JT, de Groot JF, Xiu J, Subramaniam DS, Mehta S, Gatalica Z, Swensen J, Sanai N, Spetzler D, Heimberger AB.

J Neuropathol Exp Neurol. 2018 Jun 1;77(6):437-442. doi: 10.1093/jnen/nly022.

17.

Association Between Programmed Death-Ligand 1 Expression and the Vascular Endothelial Growth Factor Pathway in Angiosarcoma.

Bagaria SP, Gatalica Z, Maney T, Serie D, Parasramka M, Attia S, Krishna M, Joseph RW.

Front Oncol. 2018 Mar 22;8:71. doi: 10.3389/fonc.2018.00071. eCollection 2018.

18.

Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes.

Domenyuk V, Gatalica Z, Santhanam R, Wei X, Stark A, Kennedy P, Toussaint B, Levenberg S, Wang J, Xiao N, Greil R, Rinnerthaler G, Gampenrieder SP, Heimberger AB, Berry DA, Barker A, Quackenbush J, Marshall JL, Poste G, Vacirca JL, Vidal GA, Schwartzberg LS, Halbert DD, Voss A, Magee D, Miglarese MR, Famulok M, Mayer G, Spetzler D.

Nat Commun. 2018 Mar 23;9(1):1219. doi: 10.1038/s41467-018-03631-z.

19.

Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy.

Gatalica Z, Xiu J, Swensen J, Vranic S.

Eur J Cancer. 2018 May;94:179-186. doi: 10.1016/j.ejca.2018.02.021. Epub 2018 Mar 20.

20.

Composition of the immune microenvironment differs between carcinomas metastatic to the lungs and primary lung carcinomas.

Senarathne W, Vranic S, Xiu J, Rose I, Gates P, Gatalica Z.

Ann Diagn Pathol. 2018 Apr;33:62-68. doi: 10.1016/j.anndiagpath.2017.12.004. Epub 2017 Dec 13.

21.

Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.

Vanderwalde A, Spetzler D, Xiao N, Gatalica Z, Marshall J.

Cancer Med. 2018 Mar;7(3):746-756. doi: 10.1002/cam4.1372. Epub 2018 Feb 13. Erratum in: Cancer Med. 2018 Jun;7(6):2792.

22.

Malignant Ewing-Like Neoplasm With an EWSR1-KLF15 Fusion: At the Crossroads of a Myoepithelial Carcinoma and a Ewing-Like Sarcoma. A Case Report With Treatment Options.

Stevens TM, Qarmali M, Morlote D, Mikhail FM, Swensen J, Gatalica Z, Siegal GP, Conry RM.

Int J Surg Pathol. 2018 Aug;26(5):440-447. doi: 10.1177/1066896918755009. Epub 2018 Feb 1.

PMID:
29390927
23.

Comprehensive molecular profiling of advanced/metastatic olfactory neuroblastomas.

Topcagic J, Feldman R, Ghazalpour A, Swensen J, Gatalica Z, Vranic S.

PLoS One. 2018 Jan 11;13(1):e0191244. doi: 10.1371/journal.pone.0191244. eCollection 2018.

24.

A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients.

Ramanathan RK, Weiss GJ, Posner RG, Rajeshkumar NV, Jameson G, Aziz M, Hoering A, Bolejack V, Maitra A, Fulk M, Stites EC, Hlavacek WS, Gatalica Z, Xiu J, Hidalgo M, Von Hoff DD, Barrett MT.

J Gastrointest Oncol. 2017 Dec;8(6):925-935. doi: 10.21037/jgo.2017.09.05.

25.

Molecular characteristics of hepatocellular carcinomas from different age groups.

Ang C, Shields A, Xiu J, Gatalica Z, Reddy S, Salem ME, Farhangfar C, Hwang J, Astsaturov I, Marshall JL.

Oncotarget. 2017 Sep 27;8(60):101591-101598. doi: 10.18632/oncotarget.21353. eCollection 2017 Nov 24.

26.

PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma.

Javed A, Arguello D, Johnston C, Gatalica Z, Terai M, Weight RM, Orloff M, Mastrangelo MJ, Sato T.

Immunotherapy. 2017 Dec;9(16):1323-1330. doi: 10.2217/imt-2017-0066.

27.

Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers.

Salem ME, Weinberg BA, Xiu J, El-Deiry WS, Hwang JJ, Gatalica Z, Philip PA, Shields AF, Lenz HJ, Marshall JL.

Oncotarget. 2017 Sep 21;8(49):86356-86368. doi: 10.18632/oncotarget.21169. eCollection 2017 Oct 17.

28.

Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients.

Heestand GM, Schwaederle M, Gatalica Z, Arguello D, Kurzrock R.

Eur J Cancer. 2017 Sep;83:80-87. doi: 10.1016/j.ejca.2017.06.019. Epub 2017 Jul 17.

29.

BRCA2, EGFR, and NTRK mutations in mismatch repair-deficient colorectal cancers with MSH2 or MLH1 mutations.

Deihimi S, Lev A, Slifker M, Shagisultanova E, Xu Q, Jung K, Vijayvergia N, Ross EA, Xiu J, Swensen J, Gatalica Z, Andrake M, Dunbrack RL, El-Deiry WS.

Oncotarget. 2017 Jun 20;8(25):39945-39962. doi: 10.18632/oncotarget.18098.

30.

Primary renal sclerosing epithelioid fibrosarcoma: a case report and review of the literature.

Torabi A, Corral J, Gatalica Z, Swensen J, Moraveji S, Bridge JA.

Pathology. 2017 Jun;49(4):447-450. doi: 10.1016/j.pathol.2017.01.010. Epub 2017 Apr 25. Review. No abstract available.

PMID:
28450092
31.

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.

Hodges TR, Ott M, Xiu J, Gatalica Z, Swensen J, Zhou S, Huse JT, de Groot J, Li S, Overwijk WW, Spetzler D, Heimberger AB.

Neuro Oncol. 2017 Aug 1;19(8):1047-1057. doi: 10.1093/neuonc/nox026.

32.

A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib.

Thorne-Nuzzo T, Williams C, Catallini A, Clements J, Singh S, Amberson J, Dickinson K, Gatalica Z, Ho SN, Loftin I, McElhinny A, Towne P.

J Thorac Oncol. 2017 May;12(5):804-813. doi: 10.1016/j.jtho.2017.01.020. Epub 2017 Jan 29.

33.

Apocrine carcinoma of the breast: A brief update on the molecular features and targetable biomarkers.

Vranic S, Feldman R, Gatalica Z.

Bosn J Basic Med Sci. 2017 Feb 21;17(1):9-11. doi: 10.17305/bjbms.2016.1811. Review.

34.

Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance).

Hubbard JM, Mahoney MR, Loui WS, Roberts LR, Smyrk TC, Gatalica Z, Borad M, Kumar S, Alberts SR.

Target Oncol. 2017 Apr;12(2):201-209. doi: 10.1007/s11523-016-0467-0.

35.

PD-L1 Status in Refractory Lymphomas.

Vranic S, Ghosh N, Kimbrough J, Bilalovic N, Bender R, Arguello D, Veloso Y, Dizdarevic A, Gatalica Z.

PLoS One. 2016 Nov 18;11(11):e0166266. doi: 10.1371/journal.pone.0166266. eCollection 2016.

36.

Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1.

Joneja U, Vranic S, Swensen J, Feldman R, Chen W, Kimbrough J, Xiao N, Reddy S, Palazzo J, Gatalica Z.

J Clin Pathol. 2017 Mar;70(3):255-259. doi: 10.1136/jclinpath-2016-203874. Epub 2016 Aug 16.

37.

Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors.

Millis SZ, Ikeda S, Reddy S, Gatalica Z, Kurzrock R.

JAMA Oncol. 2016 Dec 1;2(12):1565-1573. doi: 10.1001/jamaoncol.2016.0891.

PMID:
27388585
38.

Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.

Garber ST, Hashimoto Y, Weathers SP, Xiu J, Gatalica Z, Verhaak RG, Zhou S, Fuller GN, Khasraw M, de Groot J, Reddy SK, Spetzler D, Heimberger AB.

Neuro Oncol. 2016 Oct;18(10):1357-66. doi: 10.1093/neuonc/now132. Epub 2016 Jul 1.

39.

Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC.

Gabrielson A, Wu Y, Wang H, Jiang J, Kallakury B, Gatalica Z, Reddy S, Kleiner D, Fishbein T, Johnson L, Island E, Satoskar R, Banovac F, Jha R, Kachhela J, Feng P, Zhang T, Tesfaye A, Prins P, Loffredo C, Marshall J, Weiner L, Atkins M, He AR.

Cancer Immunol Res. 2016 May;4(5):419-30. doi: 10.1158/2326-6066.CIR-15-0110. Epub 2016 Mar 11.

40.

Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials.

Friedlander ML, Russell K, Millis S, Gatalica Z, Bender R, Voss A.

Int J Gynecol Cancer. 2016 May;26(4):648-54. doi: 10.1097/IGC.0000000000000677.

41.

Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies.

Xiu J, Piccioni D, Juarez T, Pingle SC, Hu J, Rudnick J, Fink K, Spetzler DB, Maney T, Ghazalpour A, Bender R, Gatalica Z, Reddy S, Sanai N, Idbaih A, Glantz M, Kesari S.

Oncotarget. 2016 Apr 19;7(16):21556-69. doi: 10.18632/oncotarget.7722.

42.

High microsatellite instability (MSI-H) colorectal carcinoma: a brief review of predictive biomarkers in the era of personalized medicine.

Gatalica Z, Vranic S, Xiu J, Swensen J, Reddy S.

Fam Cancer. 2016 Jul;15(3):405-12. doi: 10.1007/s10689-016-9884-6. Review.

43.

Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options.

Ang C, Miura JT, Gamblin TC, He R, Xiu J, Millis SZ, Gatalica Z, Reddy SK, Yee NS, Abou-Alfa GK.

J Surg Oncol. 2016 Jan;113(1):55-61. doi: 10.1002/jso.24086. Epub 2015 Dec 10.

PMID:
26661118
44.

Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast.

Gatalica Z, Vranic S, Ghazalpour A, Xiu J, Ocal IT, McGill J, Bender RP, Discianno E, Schlum A, Sanati S, Palazzo J, Reddy S, Pockaj B.

Oncotarget. 2016 Jan 12;7(2):1707-16. doi: 10.18632/oncotarget.6421.

45.

Molecular profiling of head and neck squamous cell carcinoma.

Feldman R, Gatalica Z, Knezetic J, Reddy S, Nathan CA, Javadi N, Teknos T.

Head Neck. 2016 Apr;38 Suppl 1:E1625-38. doi: 10.1002/hed.24290. Epub 2015 Nov 28.

46.

Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.

El-Deiry WS, Vijayvergia N, Xiu J, Scicchitano A, Lim B, Yee NS, Harvey HA, Gatalica Z, Reddy S.

Cancer Biol Ther. 2015;16(12):1726-37. doi: 10.1080/15384047.2015.1113356.

47.

Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas.

Smaglo BG, Tesfaye A, Halfdanarson TR, Meyer JE, Wang J, Gatalica Z, Reddy S, Arguello D, Boland PM.

Oncotarget. 2015 Dec 22;6(41):43594-604. doi: 10.18632/oncotarget.6202.

48.

Adenosquamous carcinoma of the pancreas: Molecular characterization of 23 patients along with a literature review.

Borazanci E, Millis SZ, Korn R, Han H, Whatcott CJ, Gatalica Z, Barrett MT, Cridebring D, Von Hoff DD.

World J Gastrointest Oncol. 2015 Sep 15;7(9):132-40. doi: 10.4251/wjgo.v7.i9.132. Review.

49.

Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers.

Wen W, Chen WS, Xiao N, Bender R, Ghazalpour A, Tan Z, Swensen J, Millis SZ, Basu G, Gatalica Z, Press MF.

J Mol Diagn. 2015 Sep;17(5):487-95. doi: 10.1016/j.jmoldx.2015.04.003.

50.

PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.

Joseph RW, Millis SZ, Carballido EM, Bryant D, Gatalica Z, Reddy S, Bryce AH, Vogelzang NJ, Stanton ML, Castle EP, Ho TH.

Cancer Immunol Res. 2015 Dec;3(12):1303-7. doi: 10.1158/2326-6066.CIR-15-0150. Epub 2015 Aug 25.

Supplemental Content

Loading ...
Support Center